Watchlist Price Alert

Moderna Inc. (MRNA)

NASDAQ: MRNA · Real-Time Price · USD

26.27

-0.45 (-1.68%)

At close: May 23, 2025, 3:59 PM

26.33

0.23%

After-hours: May 23, 2025, 05:56 PM EDT

-1.68% (1D)

Bid	26.3
Market Cap	10.16B
Revenue (ttm)	3.16B
Net Income (ttm)	-3.36B
EPS (ttm)	-8.73
PE Ratio (ttm)	-3.01
Forward PE	-3.58
Analyst	Hold

Ask	26.33
Volume	7,299,477
Avg. Volume (20D)	10,583,309
Open	26.15
Previous Close	26.72
Day's Range	25.56 - 26.49
52-Week Range	23.15 - 170.47
Beta	2.00

About MRNA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol MRNA

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for MRNA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

4 days ago

-7.82%

Moderna shares are trading lower after the company... Unlock content with Pro Subscription

4 days ago

+6.06%

Shares of vaccine stocks are trading higher following a report indicating FDA advisers will consider if COVID-19 vaccines should target the LP.8.1 subvariant for 2025-2026.

News

2 days ago · reuters.com

Moderna files application for updated COVID vaccine

Moderna said on Friday it had filed a marketing application for an updated COVID vaccine to the U.S. Food and Drug Administration.

2 days ago · accessnewswire.com

Moderna Files FDA Application for the LP.8.1 Targeting COVID-19 Vaccine

CAMBRIDGE, MA / ACCESS Newswire / May 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spike...

3 days ago · zacks.com

MRNA Stock Down on Withdrawal of FDA Filing for COVID-Flu Combo Shot

Moderna's voluntary withdrawal of the filing stems from the FDA's request for vaccine efficacy data from a phase III study on the experimental flu shot.

2 days ago · marketbeat.com

Moderna Stock Looks Ripe for a Short Squeeze

Moderna Inc. NASDAQ: MRNA is down 35% in 2025, making it one of the worst-performing stocks among medical stocks and the broader market. Not surprisingly, the stock is down over 80% in the last 12 mon...

3 days ago · zacks.com

MRNA, PFE Stocks Jump Despite FDA's Stricter Standards for COVID-19 Shots

Though the new FDA rules limit access to COVID-19 booster vaccines, the commitment to high-risk groups lifts Moderna, Pfizer and BioNTech stocks.

3 days ago · reuters.com

Moderna withdraws application for COVID-flu combination vaccine

Moderna said on Wednesday it had withdrawn the pending application for its flu and COVID combination vaccine candidate for adults aged 50 years and older.

3 days ago · accessnewswire.com

Moderna Provides Update on BLA Submission for Combination Vaccine Against Influenza and COVID-19

CAMBRIDGE, MA / ACCESS Newswire / May 21, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced that in consultation with the U.S. Food and Drug Administration (FDA), the Company has voluntarily withdra...

5 days ago · proactiveinvestors.com

Moderna shares surge as new FDA vaccine framework eases investor concerns

Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares jumped more than 6.5% on Tuesday after the US Food and Drug Administration unveiled a new framework for COVID-19 vaccine approvals that analysts said largely ...